Publications by authors named "Heinz Ludwig"

100Publications

Daratumumab: a game changer in myeloma therapy.

Authors:
Heinz Ludwig

Lancet Haematol 2020 06;7(6):e426-e427

Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, 1160 Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30105-8DOI Listing
June 2020

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Lancet Haematol 2020 Jun 30;7(6):e456-e468. Epub 2020 Apr 30.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30099-5DOI Listing
June 2020

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.

Qual Life Res 2020 Jan 24;29(1):69-79. Epub 2019 Sep 24.

Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-019-02307-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962286PMC
January 2020

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Clin Lymphoma Myeloma Leuk 2019 08 2;19(8):522-530.e1. Epub 2019 May 2.

Department of Clinical Therapeutics, University Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.04.018DOI Listing
August 2019

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 17;36(8):728-734. Epub 2018 Jan 17.

David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain; Mihaela Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo Clinic, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5032DOI Listing
March 2018

Fixed duration vs continuous therapy in multiple myeloma.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):212-222

Department of Medicine I, Center for Medical Oncology, Hematology and Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142590PMC
December 2017

The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.

Eur J Haematol 2017 Nov 5;99(5):449-458. Epub 2017 Oct 5.

Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12958DOI Listing
November 2017

Molecular mechanisms, current management and next generation therapy in myeloma bone disease.

Leuk Lymphoma 2018 01 2;59(1):14-28. Epub 2017 Jun 2.

a Laboratory of Hematology , University of Liège, GIGA-I3 , Liège , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1323272DOI Listing
January 2018

How I manage the toxicities of myeloma drugs.

Blood 2017 04 8;129(17):2359-2367. Epub 2017 Mar 8.

Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Haematology and Palliative Care, Wilhelminenspital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-01-725705DOI Listing
April 2017

Multiple myeloma: new treatments gain momentum.

Lancet 2017 02 23;389(10068):480-482. Epub 2016 Dec 23.

Department of Hematology, University Hospital Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)32405-9DOI Listing
February 2017

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Early treatment for high-risk smouldering myeloma: has the time come?

Authors:
Heinz Ludwig

Lancet Oncol 2016 08 9;17(8):1030-1032. Epub 2016 Jul 9.

Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna 1171, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30151-6DOI Listing
August 2016

Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.

Leuk Lymphoma 2016 11 21;57(11):2516-25. Epub 2016 Mar 21.

a Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology , Wilhelminen Hospital , Vienna , Austria ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2016.1151511DOI Listing
November 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0044DOI Listing
May 2016

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.

J Hematol Oncol 2016 Mar 2;9:17. Epub 2016 Mar 2.

Wilhelminen Cancer Research Institute, Department of Medicine I, Wilhelminenspital, Montleartstraße 37, 1160, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-016-0247-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776359PMC
March 2016

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494PMC
December 2015

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

J Hematol Oncol 2015 Feb 8;8:10. Epub 2015 Feb 8.

Wilhelminen Cancer Research Institute, Department of Internal Medicine I, Wilhelminenspital, Montleartstraße 37, 1160, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-014-0105-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333268PMC
February 2015

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

J Clin Oncol 2015 Feb 20;33(6):657-64. Epub 2015 Jan 20.

Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lentzsch, Columbia University College of Physicians and Surgeons, New York, NY; Faith E. Davies, Institute of Cancer Research, Sutton, United Kingdom; Noopur Raje, Massachusetts General Hospital Cancer Center; Kenneth Anderson, Dana-Farber Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Orhan Sezer, Memorial Sisli Hospital, Istanbul, Turkey; Sonja Zweegman, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Jatin Shah, MD Anderson Cancer Center, Houston, TX; Ashraf Badros, University of Maryland Medical Center, Baltimore, MD; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; Chor-Sang Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region; Jian Hou, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Artur Jurczyszyn, University Hospital, Krakow, Poland; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Bart Barlogie, University of Arkansas for Medical Sciences, Little Rock, AR; G. David Roodman, Indiana University School of Medicine, Indianapolis, IN; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; and Brian G.M. Durie, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.9961DOI Listing
February 2015

European perspective on multiple myeloma treatment strategies in 2014.

Oncologist 2014 Aug 25;19(8):829-44. Epub 2014 Jul 25.

Department of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands; Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; Department of Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain; Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy; Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy; Haemato-Oncology Unit, Royal Marsden Hospital, Surrey, United Kingdom; Hematology Service, University Hospital La Fe, Valencia, Spain; Department of Hematology, University Hospital, Leuven, Belgium; Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany; Service d'Hématologie, Centre Hospitalier Universitaire, Lille, France; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; University Hospital, Nantes, France; Karolinska Institute, Stockholm, Sweden; Department of Hematology, Center Lillebaelt, University of Southern Denmark, Odense, Denmark; Clinica Universidad de Navarra, Centro Investigaciones Medicas Aplicada, Pamplona, Spain; Department of Hemato-oncology, University of Ostrava, Ostrava, Czech Republic; University of Giessen, Giessen, Germany.

View Article

Download full-text PDF

Source
http://szpiczak.org/lang/aktualnosci/publikacje/rok_2014/The
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122482PMC
August 2014

Pharmacovigilance in practice: erythropoiesis-stimulating agents.

Cancer Med 2014 Oct 3;3(5):1416-29. Epub 2014 Jun 3.

Sundsvall Hospital, Sundsvall, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302692PMC
October 2014

Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.

Exp Hematol 2014 Jul 2;42(7):516-25. Epub 2014 Apr 2.

Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology and Hematology, Wilhelminenhospital, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2014.03.005DOI Listing
July 2014

Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation.

Leuk Lymphoma 2014 Nov 18;55(11):2520-4. Epub 2014 Mar 18.

Department of Medicine I, Center of Oncology, Hematology and Palliative Care , Wilhelminenspital, Vienna , Austria.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2014.89
Publisher Site
http://dx.doi.org/10.3109/10428194.2014.891025DOI Listing
November 2014

Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review.

Crit Rev Oncol Hematol 2014 Jan 8;89(1):1-15. Epub 2013 Nov 8.

Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428130023
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2013.10.008DOI Listing
January 2014

Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: findings from the Anemia Cancer Treatment study.

J Geriatr Oncol 2013 Apr 27;4(2):196-201. Epub 2012 Oct 27.

Center for Health Outcomes and Pharmacoeconomic Research, and Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; Matrix45, Tucson, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2012.09.058DOI Listing
April 2013

Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.

Br J Haematol 2013 Oct 19;163(2):285-6. Epub 2013 Jul 19.

Department of Internal Medicine I, Centre for Oncology and Haematology, Wilhelminenspital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12477DOI Listing
October 2013

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.

Leuk Lymphoma 2014 Jan 12;55(1):11-8. Epub 2013 Jun 12.

Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2013.797084DOI Listing
January 2014

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.

Wien Klin Wochenschr 2013 Apr 28;125(7-8):196-9. Epub 2013 Mar 28.

Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600 Wels, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-013-0345-zDOI Listing
April 2013

Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

Leuk Res 2012 Nov;36 Suppl 1:S27-34

1st Department of Medicine, Center for Oncology and Haematology, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0145-2126(12)70006-1DOI Listing
November 2012

Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.

J Cancer Res Clin Oncol 2012 Nov 22;138(11):1821-30. Epub 2012 Jun 22.

First Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-012-1259-2DOI Listing
November 2012